Summary.-The addition of misonidazole (MISO) or metronidazole (METRO) to treatment with cyclophosphamide (CY) increased delay to regrowth of 2 experimental tumours. The effect was observed for large and small tumours, was present for doses of MISO that are ineffective for killing hypoxic cells, and required that it be given with, or shortly before CY. Mice receiving combined treatment had more weight loss and myelosuppression than those receiving CY alone, and the Therapeutic Index was lower.
MISO caused a marked increase in growth delay when combined with BCNU to treat the KHT sarcoma. This effect was observed for small and large tumours, required simultaneous administration of drugs, and also led to increased host toxicity. There was no therapeutic advantage from combined treatment.
Survival of aerobic or anoxic Chinese hamster ovary (CHO) cells was assessed after exposure in vitro to serum from mice that had received CY or BCNU alone, MISO alone, or combined treatment. Results of these experiments suggest that (1) MISO delays the excretion or breakdown of active metabolites of CY, and (2) at a dose that does not kill hypoxic cells, it may selectively "sensitize" hypoxic cells (but not aerobic cells) to the action of BCNU. The presence of other undetermined interactions of BCNU and MISO is inferred from the increased toxicity to (aerobic) normal tissue.
Misonidazole or metronidazole should receiving BCNU or cyclophosphamide. CYCLOPHOSPHAMIDE (CY) was reported to kill selectively the well-oxygenated cells of a transplantable rat tumour, and to spare the hypoxic, radioresistant cells (Dixon et al., 1978) . A similar effect was reported for the action of BCNU against B]6 melanoma in mice, but CY had no selectivity for well-oxygenated cells of this tumour (Hill & Stanley, 1975) . The mechanism of these effects is unknown, but potential causes of drug resistance of hypoxic and poorly nourished cells in solid tumours include limited diffusion of the drugs or their active metabolites from blood vessels, and a lower rate of cell proliferation for poorly nourished cells than for those situated closer to blood be used with caution in patients who are vessels (Tannock, 1968 (Tannock, , 1970 Hirst & Denekamp, 1979) .
If hypoxic cells in some solid tumours are resistant to CY or BCNU, an improved therapeutic index (i.e. ratio of tumour damage to normal tissue damage) might be achieved by combining them with agents that have selective toxicity for hypoxic cells. MISO and METRO are drugs that are known to have selective toxicity for hypoxic cells in tissue culture and in spheroids (Mohindra & Rauth, 1976; Sridhar et al., 1976; Stratford & Adams, 1977; Taylor & Rauth, 1978) and have been shown to kill hypoxic (and perhaps neighbouring aerobic cells) in some, but not all mouse tumours (Foster et al., 1976; Brown, 1977;  Denekamp, 1978; Brown & Yu, 1979) .
The preceding paper (Tannock, 1980) 
MATERIALS AND METHODS
C3H male mice were used in all experiments, and the experimental tumours were the KHT fibrosarcoma and the 16/C mammary adenocarcinoma (Lin & Bruce, 1972; Corbett et al., 1978) . Characteristics of these tumours, techniques for implantation and assessment of tumour growth, and methods for measuring haemoglobin level (Hb) and white blood cell counts (WBC) on peripheral blood, have been described in the preceding paper (Tannock, 1980) . Unless stated otherwise, mice received drug treatment when their tumours were 0-3-0 5 g in size. All measurements were made without knowledge of the treatment history of the animals, and most experiments were repeated to check reproducibility.
For treatment of the mice, Cyclophosphamide (Horner), Misonidazole (Roche), and Metronidazole (Poulenc) were dissolved in saline for injection, while BCNU was dissolved in 10% ethanol. Drugs were given by i.p. injection in a fluid volume of 0.1 mg/g body weight (CY or BCNU) or 0-02-0-05 ml/g (MISO or METRO). Single injections of CY or BCNU were used in all experiments. MISO was injected usually as a single dose of 1 mg/g body weight, but multiple i.p. injections of MISO or METRO were given in some experiments in combination with CY. Nine doses of 0-2 mg/g/injection (MISO) or 0 4 mg/g/injection (METRO) were injected at 4h intervals in an attempt to sustain serum levels over 36 h (Tannock, 1980 (Tannock, 1980) show that single-dose MISO (1 mg/g), and multiple injections of either MISO or METRO have no effect on the growth of either the KHT or 16/C tumours. Single-dose MISO given after 15 Gy radiation to the 16/C tumour led to a small increase in delay to regrowth, implying some ability to kill hypoxic cells spared by radiation; in contrast, there was no increase in growth delay compared to irradiation alone of the KHT sarcoma when single-dose MISO (1 mg/g) or multiple doses of either drug were given after radiation. MISO (Hill, 1980 (Stratford & Adams, 1978) . The results of some of these experiments are shown in Fig. 3 (Fig. 3A) . The increase in growth delay after adding MISO to CY for treatment of 0 3-0 5 g tumours depended on dose of MISO, but was detectable at a dose of 0.5 mg/g body weight (Fig. 3B) . Maintaining animals in an incubator at 3700 for 4 h after treatment with MISO (1 mg/g) led to death of the animals: the warm environment presumably prevented the known effect of MISO in causing transient decrease in body temperature, and confirms a previous report of the toxicity of keeping animals warm after MISO (Gomer & Johnson, 1979 sistent change to delay in tumour regrowth for mice kept warm during and after treatment with CY alone, MISO or METRO alone, or the combination, when compared to experiments at room temperature (e.g. Fig. 3C ).
(ii) Host toxicity.-The addition of MISO or METRO to treatment with CY led to more deaths and more weight loss (Table I ). The increase in host toxicity was greater for those conditions that led to the larger increases in anti-tumour effects. In an attempt to study the effect of adding MISO to CY on Therapeutic Index, growth delay for the KHT sarcoma and host toxicity were compared for a large dose of CY, and a smaller dose combined with MISO. CY at a dose of 200 mg/kg gave a 61 mean growth delay of 17-5 days, whereas CY (75 mg/kg) +MISO (1 mg/g) gave similar or greater toxicity, but caused mean growth delay of only 10 days (Table   I ). Therapeutic Index is thus lower for combined treatment.
The addition of MISO to CY also led to greater myelosuppression. The serial removal of small blood samples from the tail veins of mice led to a fall in Hb and a compensatory increase in WBC count, and these effects were greater in mice with tumours. MISO alone had no significant effect on the Hb or WBC count, whereas CY (75 mg/kg) caused a reduction in WBC to a nadir at 3-4 days after treatment, followed by rapid recovery. The addition of MISO (1 mg/g) led to a sig- nificant decrease in the nadir of WBC count (Fig. 4) experiments the blood counts were lower after combined treatment.
(iii) Mechanism.-Serum from mice given CY was active against CHO cells in vitro, and this system provides a bioassay for active metabolites of the drug. The level of survival of CHO cells varied slightly between experiments, and the activity of the metabolites of CY decayed even when serum was frozen immediately after preparation. Thus, serum was prepared as rapidly as possible before adding to cultures of CHO cells in order to minimize variability in time of preparation.
Serum from untreated mice, and from mice that had received MISO (1 mg/g) 0 5 or 1.0 h earlier, had no effect on aerobic or hypoxic CHO cells. This result is expected because the 1:16 dilution of the serum in culture led to levels of MISO much lower than those usually lethal to hypoxic cells. Serum from mice given CY (200 mg/kg) 0 5 h earlier was active, but most of this activity was lost 1 h after treatment (Fig.5) . Serum from mice that had received CY and MISO had similar activity to serum from mice receiving CY alone at 0 5 h, but retained much greater activity at 1.0 h (Fig. 5) . There was little difference in response of aerobic and hypoxic cells. Thus MISO seems to delay the excretion or inhibit the breakdown of active metabolites of CY. delayed growth of the KHT sarcoma (Lin & Bruce, 1972) but experiments in this and other laboratories have shown the drug to be inactive against the 16/C carcinoma (Corbett et al., 1978) . Combination of BCNU with single-dose MISO led to a marked increase in effectiveness against the KHT tumour ( Fig. 6 and Table II ). The nature of the anti-tumour interaction was investigated in experiments analagous to those performed for CY. The anti-tumour effects of BCNU and MISO were observed when the drugs were given together but not when MISO preceded BCNU by 4 h. MISO led to slightly greater growth delay when combined with BCNU for treatment of small non-palpable tumours than for treatment of larger tumours (Fig. 6) . The increased effect of the combination was dependent on the dose of MISO, but was seen at doses of 05 or 075 mg/g (e.g. Fig. 6c ).
The combination of BCNU and MISO caused more deaths and more weight loss than the same dose of BCNU alone (Table  II) . For comparison of Therapeutic Index, the anti-tumour effects and toxicity of a large dose of BCNU alone were compared with those of a smaller dose of BCNIU with MISO. The data of Table II suggest about equal toxicity for the same delay in tumour growth and hence no effect on Therapeutic Index.
Treatment with BCNU had no effect on Hb level, and caused only a small decrease in WBC count. The addition of MISO had little effect on the nadir of WBC count after treatment (Table III) .
(ii) Mechanism.-Serum from mice given BCNU (66 mg/kg) 05 h earlier was active against CHO cells in vitro, and there was no difference in the response of aerobic or hypoxic CHO cells (Fig. 7) . Serum from mice treated 1 h earlier was inactive. Serum from animals receiving combined treatment 05 h before death (BCNU 66 mg/kg +MISO 1 mg/g) had similar activity for aerobic cells to that from mice receiving BCNU alone, but was much more toxic for hypoxic cells (Fig. 7) . This unexpected result has been confirmed in repeated experiments. Thus MISO, at a dose that is ineffective for killing hypoxic cells, seems capable of selectively "sensitizing" hypoxic cells to the action of BCNU.
The role of the above effect in causing the increased anti-tumour effects in vivo for the combination of BCNU and MISO also to increased toxicity. Combined treatment does not lead to therapeutic advantage, and may be detrimental. The interaction of CY and MISO seems to be due in part to a change in the pharmacokinetics of CY. Results presented in Fig. 5 , and confirmed in other experiments, have shown that the administration of MISO with CY leads to a longer retention in serum of metabolites toxic for mammalian cells. This mechanism probably causes the increased growth delay found in both experimental tumours, and the increase in host toxicity, including myelosuppression. The cause of the decrease in Therapeutic Index for the combination of MISO and a moderate dose of CY, as compared to a higher dose of CY alone, is undetermined. The change in pharmacokinetics might lead to selective retention of those metabolites of CY that have a high ratio of host toxicity to antitumour effects, or there may be other independent drug reactions that lead to an increase in deaths and weight loss.
The interaction of BCNU and MISO is complex. The combination has been shown to cause an increase in non-specific host toxicity, and the nature of this interaction is unknown. However, MISO, at a concentration ineffective for killing hypoxic cells, has been shown to give a selective "sensitization" for the action of BCNU against hypoxic cells. There was a similar effect when BCNU and MISO were added directly to cultures of CHO cells. Experiments are being performed in tissue culture to characterize this interaction, and will be reported separately. BCNU was found to spare hypoxic cells in one experimental tumour (Hill & Stanley, 1975) but it remains uncertain whether the observed interaction of BCNU and MISO for hypoxic cells is a cause of the increased activity of the combination for the KHT tumour.
The present experiments, and those of the previous paper (Tannock, 1980) , were undertaken to seek evidence for killing by nitroimidazoles of hypoxic cells which might have been spared by conventional chemotherapy, and to provide data on drug interactions prior to the use of such combinations in man. There is little evidence from the present experiments for selective killing of hypoxic cells in murine tumours by MISO or METRO given with anti-cancer drugs, since anti-tumour effects have been accompanied by equal or even greater host toxicity. Little is known about the relative response ofaerobic and hypoxic clonogenic tumour cells to chemotherapy. Such information is important, for if surviving cells were predominantly hypoxic, nitroimidazoles and other drugs should be selected and developed for their hypoxic cell toxicity as well as for hypoxiccell radiosensitization. The added possibility of hypoxic-cell "chemosensitization", suggested by the above results for BCNU and MISO is another potentially exploitable mechanism, despite the lack of therapeutic advantage for the KHT sarcoma.
A major conclusion of the present studies is that MISO or METRO lead to a marked increase in host toxicity when combined with several anti-cancer drugs. Combination of misonidazole or metronidazole with cyclophosphamide or BCNU in patients should be undertaken with great caution, and should follow the design of a Phase I trial.
